Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas - Fierce Biotech

Google News1/15/2026 – 1/16/2026

Summary

Ocugen has announced positive preliminary Phase 2 data from its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The company released 12-month data from the Phase 2 ArMaDa trial, indicating that the gene therapy continues to slow damage in geographic atrophy. This development positions Ocugen in competition with Apellis and Astellas.

Share:XRedditLinkedIn

Advertisement

Lindy Score Breakdown (V4.2)

93d
Age
1
Sources
from cluster
2200
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^2200/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^2200/48 = 0.000000) reduced it below 0.5

Score BreakdownRisk 50

Source Reputation: Low-trust source (6/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 92 days - proven survivor

Stories gain Lindy status through source reputation, network consensus, and time survival.

Breaking Similar stories

Anti-Lindy Similar stories